Cargando…

Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”

Detalles Bibliográficos
Autores principales:	Rege, Bhaskar, McGrory, James, Gasper, Sabina, McDonnell, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674725/ https://www.ncbi.nlm.nih.gov/pubmed/36357768 http://dx.doi.org/10.1007/s40273-022-01200-3

Ejemplares similares

Response to Comment on “An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”
por: Piena, Marjanne A., et al.
Publicado: (2022)

An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia
por: Piena, Marjanne A., et al.
Publicado: (2021)

Comment on “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use”
por: Still, Daniel, et al.
Publicado: (2023)

Letter to the Editor on “Disassociation of a Cold-Welded Bimodular Titanium Femoral Stem by Intraoperative Ice Cooling”
por: McGrory, Brian J.
Publicado: (2020)

Development of pharmacoeconomics guidelines for India
por: Thomas, Dixon, et al.
Publicado: (2014)

Pharmacoeconomic evaluations in the treatment of actinic keratoses
por: Tolley, Keith, et al.
Publicado: (2017)

Authors’ Reply to Ganijee et al.: “Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults”
por: Boettcher, Michael, et al.
Publicado: (2023)

Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
por: Akizawa, Tadao, et al.
Publicado: (2019)

Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
por: Webster, Christopher J., et al.
Publicado: (2019)

Pharmacoeconomical Concept in the Book of Rhazes, 10(th) Century AD
por: Hosseinkhani, Ayda, et al.
Publicado: (2019)

Comment on “Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review”
por: Todtenkopf, Mark S., et al.
Publicado: (2023)

Anterior Subluxation after Total Hip Replacement Confirmed by Radiographs: Report of Two Cases
por: McGrory, Conor P., et al.
Publicado: (2011)

Systematic review of pharmacoeconomic models for schizophrenia
por: Zhou, Junwen, et al.
Publicado: (2018)

Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’
por: Koren, Andrew, et al.
Publicado: (2021)

Comment on “Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison” [Letter]
por: Rege, Bhaskar, et al.
Publicado: (2023)

Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”
por: Periclou, Antonia, et al.
Publicado: (2019)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Pharmacokinetic‐pharmacodynamic integration of enrofloxacin and its metabolite ciprofloxacin in buffalo calves
por: Daundkar, Prashant S., et al.
Publicado: (2015)

Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor
por: Cubała, Wiesław Jerzy, et al.
Publicado: (2010)

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
por: Ravandi, F, et al.
Publicado: (2015)

Why case reports matter
por: McGrory, Brian J.
Publicado: (2015)

The case for open access
por: McGrory, Brian J.
Publicado: (2015)

Note from the Editor
por: McGrory, Brian J.
Publicado: (2015)

Note from the Editor
por: McGrory, Brian J.
Publicado: (2016)

Note from the Editor
por: McGrory, Brian J.
Publicado: (2017)

In the zone
por: McGrory, Brian J.
Publicado: (2018)

Note from the Editor
por: McGrory, Brian J.
Publicado: (2018)

Note from the Editor
por: McGrory, Brian J.
Publicado: (2015)

Note from the Editor
por: McGrory, Brian J.
Publicado: (2019)

Viewpoint, a new type of Arthroplasty Today manuscript
por: McGrory, Brian J.
Publicado: (2019)

Note from the Editor
por: McGrory, Brian J.
Publicado: (2019)

Continuing medical education and Arthroplasty Today
por: McGrory, Brian J.
Publicado: (2019)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012)

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021)

Formulary Management Methods and Pharmacoeconomics
por: Curtiss, Frederic R.
Publicado: (2003)

Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
por: Focosi, Daniele, et al.
Publicado: (2023)

Comment on: Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants
por: Standing, Joseph F
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Letter in response to the article: Vitamin D concentrations and COVID-19 infection in UK biobank (Hastie et al.)
por: Grant, W.B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bm5sllslqtla2n01h54ehj6ecr